Status:
COMPLETED
PTG-100 for Patients With Celiac Disease
Lead Sponsor:
Nielsen Fernandez-Becker
Collaborating Sponsors:
Protagonist Therapeutics, Inc.
Conditions:
Celiac Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The goal of this study is to learn whether or not the drug PTG-100 can reduce or prevent inflammatory injury to the small intestine that occurs when people with celiac disease eat food products contai...
Eligibility Criteria
Inclusion
- Diagnosis of celiac disease
Exclusion
- Active GI disease or history of clinically significant diseases
- Diagnosis of Crohn's disease or ulcerative colitis.
Key Trial Info
Start Date :
February 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 3 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04524221
Start Date
February 26 2021
End Date
April 3 2022
Last Update
May 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Redwood City, California, United States, 94063